The first approved medical therapy is mifepristone, a nonselective GR antagonist, designated for adult patients with glucose intolerance or type 2 diabetes mellitus coupled with Cushing’s syndrome and are either ineligible for surgery or have undergone unsuccessful surgery [5]. The gene discussed is NR3C1; the disease is Cushing syndrome.